A newly discovered cancer trick that weakens immunotherapy may be stopped by everyday statins.

Schlesinger: For advanced cSCC, immunotherapy has been a game-changer. The first immunotherapy drugs approved in the space were PD-1 inhibitors such as cemiplimab (Libtayo; Regeneron) and ...

Association of HIPEC response in ovarian cancer with PI3K/RAS/Notch gene signatures: A whole transcriptomic analysis of U.S. and French HIPEC treated ovarian cancer patients. This is an ASCO Meeting ...

Nigeria on Wednesday launched its first clinical trial using immunotherapy to treat colorectal cancer, a move doctors say ...

With Bristol Myers Squibb (BMS) now rolling out the SC version of rival nivolumab (Opdivo Qvantig), the shift from 30-minute intravenous (IV) infusion to 5-minute SC injection could be one of the most ...

Pfizer’s top cancer drugs are small molecules, but dealmaking has expanded the pharmaceutical giant’s portfolio and pipeline with biologic medicines. Its latest deal puts it in a camp of companies ...

Immune checkpoint therapy, particularly anti-PD-1/PD-L1 immunotherapy, have achieved significant results in the treatment of various tumors. However, most cancer patients show a low response rate to ...

Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small-cell lung cancer will benefit from immunotherapy.

Scientists at the Icahn School of Medicine at Mount Sinai have identified an important immune response that helps explain why some cancer patients benefit from immunotherapy while others do not. In a ...